Furthermore, variability in the seeding activity of tau between patients was shown to correlate with differences in clinical course and with immune system involvement, suggesting that there may be molecular subtypes of PSP that can be distinguished at a biochemical level. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.